Nalu Bio

About Nalu Bio

Nalu Bio is focused on unlocking the endocannabinoid system (ECS) to address global health challenges caused by modern lifestyles, such as inflammatory, immune, and metabolic diseases. They aim to leverage the ECS's potential to develop reliable, non-addictive therapeutics.

Products & Services

ECS Technology Platform:An AI-powered drug discovery platform that is 5X faster and lower in cost, trained on 90,000 compounds and 25 GPCR receptors, generating thousands of novel ECS compounds daily.

ECS Pipeline:A pipeline of non-addictive ECS-based compounds designed to address health challenges and fill the patent cliff.

Specialties

Endocannabinoid System (ECS) AI-powered Drug Discovery Non-addictive Therapeutics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 12000000 MR: - FA: $12 million FAN: 12000000	D: 2023-02-28 FD: 2023-02-28	9 investors

Series A Latest

2023-02-28

$12.0M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

C

Caitlyn Krebs

Co-founder + CEO

G

Grazia Piizzi

Chief Scientific Officer

A

Alex Dorenbaum

Chief Medical Officer

G

Glenn Sammis

Chief Chemist

M

Mehdi Haghdoost

Director of Medicinal Chemistry

B

Bill Kehoe

Chief Financial Officer

View 12 more team members with Pro

Unlock Full Team Directory

Recent News

Nalu Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised